Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $80M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 18.07.2023 | MPM Capita... | mpmcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.07.2023 | Series A | $80M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 11.07.2023 | Crossbow Therapeutics Raises $80M in Series A Financing | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing a novel class of antib... | finsmes.co... |
| - | Crossbow Therapeutics | “Expanding the reach of antibody therapeutics. Determined to revolutionize the reach of cancer trea... | fastfounde... |